386 - Breast cancer patients with HER2neu overexpression: relationship among clinicopathological characteristics and local/distant recurrences and survival

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Breast Cancer
Aetiology, epidemiology, screening and prevention
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Carla Bellido - Ribes
Authors C. Bellido - Ribes1, S. Gonzalez2, A. Garcia3, V. Obadia2, R. Bastus4, J. Fernández4, A. Aguilar4, L. Cirera4
  • 1Medical Oncology, Mutua terrassa University Hospital, 08221 - Terrassa/ES
  • 2Medical Oncology, Hospital Mutua Terrassa, 08221 - Terrassa/ES
  • 3Breast Unit, Departament Of Gynecology, Hospital mutua terrassa, 08221 - Terrassa/ES
  • 4Medical Oncologyst, Hospital Mutua Terrassa, 08221 - Terrassa/ES

Abstract

Objectives

The aim of this study was to correlate the overexpression of HER2 with clinical pathologic characteristics and its influence on local/distant recurrence and survival.

Methods

From 1998 to 2010, prospective data of 146 patients with invasive breast cancer with HER-2 overexpression was studied. The sample was divided into three groups: Negative hormonal receptors (NHR); Luminal B1 (Estrogen receptor +/-, Progesterone receptor +), Luminal B2 (Estrogen receptor +, Progesterone receptor -). Histological type (HT), size tumor (T), differentiation grade (DG), and nodal status were determined. Correlation with local and distant recurrence, and 5-year overall survival was done.

Results

NHR: 33.5%, luminal B1: 47.5%; Luminal B2: 19% Clinical pathologic characteristics:

Age (%) Size(%) HT (%)
<50 50-69 >70 T1 T2 T3 T4 Ductal Lobular
NHR 23 51 26 39 37 4 10 98 2
Luminal B1 33 51 16 51 39 9 1 99 1
Luminal B2 22 64 14 53 43 30 4 96 4

DG (%) Nodal Status
G1 G2 G3 Negative Positive
NHR 0 21 79 59 41
Luminal B1 11 37 52 48 52
Luminal B 0 28 73 57 43

Local and distant recurrence and overall survival at 5 years follow-up:

Local Recurrence(%) Metastasis Recurrence(%) Overall Survival (%)
NHR 6 20 81.5
Luminal B1 2 8 88.5
Luminal B2 4 15 86.5

Conclusions

Patients with NHR and patients with PR- had more aggressive differentiation grade, less axillary infiltration and increased risk of distant metastasis. At 5-year follow-up, overall survival was better in the PR+ group.

Disclosure

All authors have declared no conflicts of interest.